Somatostatin administration following pancreateoduodenectomy: a case-matched comparison according to surgical technique, body mass index, American Society of Anesthesiologists’ score and Fistula Risk Score

Niccolò Furbetta1 · Desirée Gianardi1 · Simone Guadagni1 · Gregorio Di Franco1 · Matteo Palmeri1 · Matteo Bianchini1 · Kevin Pisani1 · Giulio Di Candio1 · Luca Morelli1,2

Received: 27 July 2020 / Accepted: 20 October 2020 / Published online: 3 December 2020 © The Author(s) 2020

Abstract
Purpose This study evaluated the controversial role of somatostatin after pancreateoduodenectomy (PD), stratifying patients for the main risk factors using the most recent postoperative pancreatic fistula (POPF) classification and including only patients who had undergone PD with the same technique of pancreatojejunostomy.

Methods Between November 2010 and February 2020, 218 PD procedures were carried out via personal modified pancreatojejunostomy (mPJ-PD). Somatostatin was routinely administered between 2010 and 2016, while from 2017, 97 mPJ-PD procedures without somatostatin (WS) were performed. The WS group was retrospectively compared with a control (C) group obtained with one-to-one case–control matching according to the body mass index, American Society of Anesthesiologists’ score, and Fistula Risk Score (FRS).

Results A total of 144 patients (72 WS group versus 72 C group) were compared. In the WS group, 6 patients (8.3%) developed clinically relevant POPF, compared with 8 patients (11.1%) in the C group (p = 0.656). In addition, on analyzing the subgroup of high-risk patients according to the FRS, we did not note any significant differences in POPF occurrence. Furthermore, no marked differences in the morbidity or mortality were found. Digestive bleeding and diabetes onset rates were higher in the WS group than in the control group, but not significantly so.

Conclusions The results of the present study confirm no benefit with the routine administration of somatostatin after PD to prevent POPF, even in high-risk patients. However, a possible role in the prevention of postoperative digestive bleeding and diabetes was observed.

Keywords Somatostatin analogues · Pancreatoduodenectomy · Somatostatin prophylaxis · POPF

Introduction
In recent decades, technical evolution and perioperative management improvements have drastically reduced mortality following pancreateoduodenectomy (PD) in high-volume centers [1]. However, morbidity rates remain as high as 28–58%, with post-operative pancreatic fistula (POPF) still the main cause of this high morbidity rate, showing a reported incidence of 2–42.5% [2]. The differences in the incidence of POPF may be due to the varying definitions reported in published studies. Indeed, in 2005, the International Study Group on Pancreatic Fistulas (ISGPF) released a universal classification of fistulae, with Grade B and C fistulae considered clinically relevant [3]. In 2016, the ISGPF reconvened as the International Study Group on Pancreatic Surgery (ISGPS) to update and revise the POPF definition and grading system [4], and the criteria for its diagnosis underwent a radical change.

Significant efforts have been put toward identifying risk factors able to predict POPF formation over the years. The
most well-validated predictive model is the Fistula Risk Score (FRS), which stratifies the patient risk according to the pancreatic duct diameter, gland texture, intraoperative blood loss, and pathology [5–7]. Furthermore, several studies have demonstrated a correlation between the development of POPF and other patient-related factors, such as high values for the body mass index (BMI) and American Society of Anesthesiologists’ (ASA) score [8].

Since POPF strongly influences both the short- and long-term outcomes following PD [9–12], various strategies have been adopted in an attempt to reduce the rate of this complication, including the use of fibrin sealants, transanastomotic stents, different techniques for fashioning the pancreatojejunostomy, and the administration of somatostatin analogues (SAs) [13]. Klempa et al. [14] first reported that somatostatin reduced the incidence of complications following PD. Since then, numerous trials have investigated the efficacy of the administration of somatostatin and its analogues to inhibit pancreatic exocrine secretions in an attempt to reduce the risk of POPF.

However, several major concerns still afflict the majority of trials available in the literature, such as marked heterogeneity regarding surgeons and institutional experience, the type of pancreatic resection, and reconstruction technique, as well as the POPF definition and classification and, above all, the lack of fistula risk stratification. For these reasons the strength of recommendations concerning the use of SAs in patients undergoing pancreatic resections remains low, and a majority of centers no longer use them routinely. Nevertheless, a consensus has not yet been reached, and the current position statement of the ISGPS [15] affirms that the routine use of SA may be relevant in high-risk patients.

The primary aim of this study was to evaluate the role of somatostatin in preventing POPF after PD, including an analysis of the data from a tertiary care center by stratifying the risk of POPF using the most relevant risk factors (the FRS [5–7], BMI, and ASA [8, 16]), adopting the updated 2016 ISGPS criteria for POPF definition and classification [4], and including only patients who had undergone PD with the same standardized technique of pancreatojejunostomy [17]. The secondary aim of the study was to evaluate the outcome of patients undergoing pancreatoduodenectomy with and without somatostatin administration in terms of morbidity and mortality.

**Methods**

**Data collection**

From October 2008 to February 2020, a total of 601 pancreatic resection procedures were performed at the General Surgery Unit, University of Pisa. Among these, 382 were PD, of which 218 were carried out with a personal modified invaginated pancreatojejunostomy technique (mPJ), introduced in November 2010 [17]. Somatostatin was routinely administered after PD with the mPJ technique (mPJ-PD) between November 2010 and December 2016, while from January 2017, the policy was completely changed, and somatostatin prophylaxis was never administered, not even in high-risk patients. Therefore, from January 2017 to February 2020, 97 mPJ-PD procedures without somatostatin (WS group) were performed. In this cohort, neither somatostatin nor its analogues were administered as prophylaxis, only being given as adjuvant therapy in select patients who developed clinically relevant POPF.

In the present study, the WS group was retrospectively compared with a control (C) group of mPJ-PD in which somatostatin had been routinely administered. The two groups were matched using a one-to-one case–control design, where each patient of the WS group was matched with a comparable patient according to the FRS [5–7], ASA score [8], BMI, and pancreatojejunostomy technique (mPJ). The two matched groups were compared for their intra- and post-operative outcomes, with particular attention paid to POPF. Data were retrieved from the institutional prospectively collected dedicated database. In analyzing the data, the first 20 patients who had undergone mPJ-PD were removed to eliminate bias related to the learning curve of the new modified technique.

The preoperative patient characteristics were recorded, including the age, gender, BMI, nutritional status, ASA score, and comorbidities. The preoperative workup included abdominal ultrasonography, chest radiography, abdomen computed tomography (CT), and/or magnetic resonance imaging findings. Patients who had undergone preoperative CT were excluded from the matching in order to reduce possible selection bias. Perioperative data included the operative findings, operative time, estimated blood loss, need for blood transfusions, pancreatic texture, pancreatic duct size, need and type of vascular resection, and pathological findings. Based on the gland texture, pancreatic duct size, histological diagnosis, and estimated intraoperative blood loss, the FRS was calculated, and patients were stratified into four risk classes: negligible, low, moderate, and high.

Postoperative data included the length of hospital stay and morbidity. Morbidity included intra-abdominal fluid collection, wound infection, POPF, delayed gastric emptying, biliary fistula, bleeding, intestinal obstruction, and pulmonary or urinary tract infections. Postoperative complications were graded using the Clavien–Dindo classification [18]. Re-admission rates within 90 days were also tabulated, as well as mortality within 30 days after surgery.
Surgical and perioperative management

All procedures were performed with the same mPJ technique [17], which merges the two most popular methods of creating PJ reported in the literature [19–21], combining certain technical aspects of end-to-side duct-to-mucosa and some invagination technique along with personal technical details. Since the introduction of this new PJ technique, the perioperative management of patients undergoing PD at our institution has been standardized with regard to the surgical technique, drain placement and removal policy, timing and content of meals, and evaluation and management of POPF. In particular, anastomotic drains were placed in all cases, and POPF occurrence was assessed with daily measurement of the drainage output volume and amylase content on post-operative days 3 and 5 and, when positive, every three days until drain removal. In cases with multiple drains, the highest concentration of drain amylase was used to ascertain whether or not a biochemical leak had occurred. The drainage tubes were removed on POD 5 in patients judged to have an ISGPS grade of “none” and without any signs of intra-abdominal infection or decreasing amylase concentrations from peripancreatic drains.

An abdominal ultrasound examination was performed as a first-level exam in case of any clinical suspicion of intra-abdominal complications and then such cases are followed up by CT. Intra-abdominal collections caused by POPF were drained with an interventional ultrasound procedure, usually involving the placement of a pigtail catheter in the collection in the first instance, with CT-guided pigtail placement reserved for a failed ultrasound-guided procedure. When prophylactic somatostatin was used, it was initiated intra-operatively at the beginning of the mPJ fashioning at 3 mg/12 h intravenously and continued for 5 days. As prophylaxis for postoperative digestive bleeding and to prevent the possible occurrence of an anastomotic gastric ulcer, a proton pump inhibitor (PPI; Pantoprazole) was administered at 40 mg/day intravenously, shifting to oral administration as soon as a semi-liquid diet was well tolerated.

Fistula classification

POPF was retrospectively classified according to the updated 2016 ISGPS criteria [4]. An asymptomatic POPF that did not require specific treatment and was characterized by elevated drain amylase values (> 3× upper limit of normal serum amylase concentration) was considered a biochemical leak. Patients who had biochemical leaks with clinical scenarios, such as prolonged management of a surgical drain exceeding 21 days or percutaneous drain placement for abdominal fluid collection, were considered to have Grade B POPF. Grade C POPF classification, which necessitated a major change in the postoperative management and required aggressive clinical treatment, was characterized by any of the following: reoperation under general anesthesia, POPF-related organ failure, or POPF-related death.

Statistical analyses

The WS and C groups were selected from our prospectively collected institutional database of pancreatic resection using a one-to-one case-matched methodology with Student’s t test, where each patient of the WS group was matched with a patient of the C group using the following criteria: gender, age, BMI, ASA score and Fistula Risk Score. Continuous variables are shown as the mean ± standard deviation and were compared using Student’s t test. Variables with a non-normal distribution are expressed as the median (IQ1, IQ3) and were compared using Wilcoxon’s test. The chi-square test (or Fisher’s exact test) was used to define associations between categorical factors and the two groups. p < 0.05 was considered statistically significant.

Results

The baseline characteristics of the entire cohort of patients who had undergone mPJ-PD at our institute are shown in Table 1, excluding those of the first 20 who were removed to eliminate possible bias related to the learning curve of the new modified technique.

The study sample consisted of 144 patients (72 in the WS group and 72 in the C group). The baseline characteristics of the two matched groups are summarized in Table 2, and the matching criteria are shown in Table 3.

Each group of patients was stratified according to the FRS into 4 subgroups: negligible risk (6 patients, 8.3%, 0 FRS points), low risk (14 patients, 19.4%, 1–2 FRS points), intermediate risk (41 patients, 56.9%, 3–6 FRS points), and high risk (11 patients, 15.3%, 7–10 FRS points).

For the primary endpoint of the study, POPF was registered in 16 patients (10 BL and 6 grade B fistulas) of the WS group; whereas in the C group, 15 patients developed POPF (7 BL, 7 Grade B, and 1 Grade C), without no significant difference noted between the two groups (p = 0.656). Therefore, the rates of clinically relevant POPF were 8.3% in the WS group (6/72 patients) and 11.1% in the C group (8/72 patients), without significant differences. On analyzing
Table 1 Baseline characteristics of the entire cohort of patients who had undergone mPJ-PD before (2010–2016) and after (2017–2020) the routine administration of somatostatin prophylaxis

| Characteristic                          | 2010–2016 (101 patients) | 2017–2020 (97 patients) | p value |
|----------------------------------------|---------------------------|--------------------------|---------|
| Male, n (%)                            | 53 (52.5)                 | 53 (54.6)                | 0.760   |
| Age (years), mean ± SD                 | 68.2 ± 3.0                | 70.3 ± 10.5              | 0.213   |
| Glucose level (mg/dl), mean ± SD       | 119.9 ± 43.8              | 128.0 ± 43.2             | 0.275   |
| Morbidity                              |                           |                          |         |
| Diabetes, n (%)                        | 18 (17.8)                 | 26 (26.8)                | 0.129   |
| Cardiopulmonary disease, n (%)         | 24 (23.8)                 | 22 (22.7)                | 0.857   |
| Nutritional status                     |                           |                          |         |
| Serum protein (g/dl), mean ± SD        | 6.58 ± 0.82               | 6.76 ± 0.86              | 0.223   |
| Albumin (g/dl), mean ± SD              | 3.55 ± 0.60               | 3.52 ± 0.58              | 0.781   |
| BMI (kg/m²), mean ± SD                 | 24.88 ± 3.75              | 24.64 ± 3.79             | 0.660   |
| Symptoms                               |                           |                          |         |
| Jaundice, n (%)                        | 50 (49.5)                 | 56 (57.7)                | 0.246   |
| Abdominal pain, n (%)                  | 30 (29.7)                 | 32 (33.0)                | 0.618   |
| Weight loss, n (%)                     | 19 (18.8)                 | 20 (20.6)                | 0.749   |
| Digestive symptoms, n (%)              | 22 (21.8)                 | 18 (18.6)                | 0.572   |
| Preoperative RT/CT, n (%)              | 2 (2.0)                   | 7 (7.2)                  | 0.077   |
| Pathological findings                  |                           |                          | 0.330   |
| PDAC, n (%)                            | 51 (50.5)                 | 60 (61.9)                |         |
| IPMN, n (%)                            | 4 (4.0)                   | 1 (1.0)                  |         |
| Pancreatic NET, n (%)                  | 7 (6.9)                   | 2 (2.0)                  |         |
| Other pancreatic neoplasm, n (%)       | 7 (6.9)                   | 6 (6.2)                  |         |
| Cholangiocarcinoma, n (%)              | 11 (10.9)                 | 6 (6.2)                  |         |
| Ampullary neoplasm, n (%)              | 10 (9.9)                  | 14 (14.4)                |         |
| Gastrointestinal neoplasm, n (%)       | 9 (8.9)                   | 7 (7.2)                  |         |
| Others, n (%)                          | 2 (2.0)                   | 1 (1.0)                  |         |

Table 2 Baseline characteristics of the two matched groups

| Characteristic                          | C group | WS group | p value |
|----------------------------------------|---------|----------|---------|
| Male, n (%)                            | 36 (50) | 41 (56.9) | 0.404   |
| Age (years), mean ± SD                 | 68.71 ± 13.22 | 69.16 ± 10.79 | 0.822   |
| BMI (kg/m²), mean ± SD                 | 23.96 ± 3.18 | 24.51 ± 3.33 | 0.322   |
| Morbidity                              |         |          |         |
| Hypertension, n (%)                    | 36 (50.0) | 48 (66.7) | 0.043   |
| Diabetes, n (%)                        | 13 (18.1) | 18 (25.0) | 0.311   |
| Cardiovascular disease, n (%)          | 15 (20.8) | 12 (16.7) | 0.522   |
| Pulmonary disease, n (%)               | 3 (4.2)  | 0 (0)    | 0.080   |
| Glucose level (mg/dl), mean ± SD       | 117.15 ± 46.67 | 127.29 ± 40.35 | 0.200   |
| Nutritional status                     |         |          |         |
| Serum protein (g/dl), mean ± SD        | 6.77 ± 0.88 | 6.59 ± 0.84 | 0.244   |
| Albumin (g/dl), mean ± SD              | 3.53 ± 0.59 | 3.56 ± 0.61 | 0.727   |
| Symptoms, n (%)                        | 58 (80.6) | 59 (81.9) | 0.831   |
| Jaundice, n (%)                        | 35 (48.6) | 40 (55.6) | 0.404   |
| Abdominal pain, n (%)                  | 20 (27.8) | 24 (33.3) | 0.469   |
| Weight loss, n (%)                     | 15 (20.8) | 11 (15.3) | 0.386   |
| Digestive symptoms, n (%)              | 16 (22.2) | 12 (16.7) | 0.400   |
| History of abdominal surgery, n (%)    | 42 (58.3) | 44 (61.1) | 0.734   |

*PDAC* pancreatic ductal adenocarcinoma, *IPMN* intraductal papillary mucinous neoplasm, *NET* neuroendocrine tumor, *BMI* body mass index, mPJ-PD pancreatoduodenectomy via personal modified pancreatojunostomy

*BMI* body mass index
For the secondary endpoint of the study, no marked differences were found in terms of the length of the hospital stay (19.57 days in C group versus 19.75 days in WS group, \( p = 0.924 \)) and postoperative complications. The rate of digestive bleeding was higher in the WS group (7 patients, 9.7%) than in the C group (2 patients, 2.8%) (\( p = 0.085 \)). In addition, the rate of diabetes onset was higher in the WS group (25%) than in the C group (12.5%), almost reaching the statistical significance (\( p = 0.055 \)). No marked difference was noted in the 30-day mortality rates, with 2 cases in the WS group (2.8%) and 3 in the C group (4.2%); (\( p = 0.6 \)). Postoperative data are summarized in Table 6.

---

### Table 3 Matching criteria

|               | C group | WS group | \( p \) value |
|---------------|---------|----------|---------------|
| BMI           |         |          |               |
| Underweight, \( n \) (%) | 2 (2.8) | 2 (2.8) | 1             |
| Normal, \( n \) (%)         | 41 (56.9) | 41 (56.9) |               |
| Overweight, \( n \) (%)      | 26 (36.1) | 26 (36.1) |               |
| Obese, \( n \) (%)           | 3 (4.2)   | 3 (4.2)   |               |
| ASA score       |         |          |               |
| ASA II, \( n \) (%)          | 17 (23.6) | 17 (23.6) | 1             |
| ASA III, \( n \) (%)         | 47 (65.3) | 47 (65.3) |               |
| ASA IV, \( n \) (%)          | 8 (11.1)  | 8 (11.1)  |               |
| Fistula Risk Score |      |          |               |
| Negligible, FRS = 0, \( n \) (%) | 6 (8.3) | 6 (8.3) | 1             |
| Low, FRS = 1–2, \( n \) (%)  | 14 (19.4) | 14 (19.4) |               |
| Intermediate, FRS = 3–6, \( n \) (%) | 41 (56.9) | 41 (56.9) |               |
| High, FRS = 7–10, \( n \) (%) | 11 (15.3) | 11 (15.3) |               |

*BMI body mass index, ASA American society of anesthesiologists’ score, FRS fistula risk score*

### Table 4 Intraoperative data and pathological results

|                               | C group         | WS group        | \( p \) value |
|-------------------------------|-----------------|-----------------|---------------|
| Operative time (min), mean ± SD | 430.28 ± 75.52  | 412.07 ± 72.76  | 0.143         |
| Robot-assisted surgery, \( n \) (%) | 0 (0)          | 2 (2.8)         | 0.154         |
| Vascular resection, \( n \) (%) | 6 (8.3)         | 12 (16.7)       | 0.131         |
| Soft pancreatic texture, \( n \) (%) | 35 (48.6)     | 38 (52.8)       | 0.617         |
| Pancreatic duct size          |                 |                 | 0.486         |
| \( ≥ 5 \) mm, \( n \) (%)    | 25 (34.7)       | 16 (22.2)       |               |
| \( 4 \) mm, \( n \) (%)       | 15 (20.8)       | 17 (23.6)       |               |
| \( 3 \) mm, \( n \) (%)       | 12 (16.7)       | 12 (16.7)       |               |
| \( 2 \) mm, \( n \) (%)       | 8 (11.1)        | 13 (18.1)       |               |
| \( ≤ 1 \) mm, \( n \) (%)     | 12 (16.7)       | 14 (19.4)       |               |
| Blood loss                    |                 |                 | 0.088         |
| \( ≤ 400 \) ml, \( n \) (%)  | 63 (87.5)       | 53 (73.6)       |               |
| \( 401–700 \) ml, \( n \) (%) | 9 (12.5)        | 18 (25)         |               |
| \( ≥ 700 \) ml, \( n \) (%)   | 0 (0)           | 1 (1.4)         |               |
| Pathological findings         |                 |                 |               |
| PDAC, \( n \) (%)             | 34 (47.2)       | 46 (63.9)       |               |
| IPMN, \( n \) (%)             | 2 (2.8)         | 1 (1.4)         |               |
| Pancreatic NET, \( n \) (%)   | 4 (5.6)         | 1 (1.4)         |               |
| Other pancreatic neoplasm, \( n \) (%) | 4 (5.6) | 5 (6.9) |               |
| Cholangiocarcinoma, \( n \) (%) | 9 (12.5)       | 3 (4.2)         |               |
| Ampullary neoplasm, \( n \) (%) | 9 (12.5)       | 10 (13.9)       |               |
| Gastrointestinal neoplasm, \( n \) (%) | 8 (11.1) | 6 (8.3) |               |
| Others, \( n \) (%)           | 2 (2.8)         | 0 (0.0)         |               |
| PDAC staging                  |                 |                 | 0.006         |
| IA                            | 0 (0.0)         | 5 (10.9)        |               |
| IB                            | 2 (5.9)         | 4 (8.7)         |               |
| IIA                           | 6 (17.6)        | 1 (2.2)         |               |
| IIB                           | 21 (61.8)       | 19 (41.3)       |               |
| III                           | 5 (14.7)        | 17 (37.0)       |               |

*PDAC pancreatic ductal adenocarcinoma, IPMN intraductal papillary mucinous neoplasm, NET neuroendocrine tumor, SD standard deviation*
Discussion

For years, surgeons have explored surgical techniques and medical interventions with the goal of preventing POPF, but none have led to the widespread adoption of a new standard of care.

Somatostatin is an endogenous tetradecapeptide with a wide spectrum of action, as it inhibits pancreatic exocrine, biliary, and small bowel secretions and increases the net absorption of water and electrolytes [22]. The concept of inhibiting exocrine pancreatic secretion to prevent postoperative complications originated in 1979, when Klempa et al. [14] first reported that somatostatin reduced the incidence of complications following PD. As somatostatin has a short half-life of between 1 and 2 min, several analogues have been developed to avoid the need for continuous intravenous infusion. The octapeptide octreotide has a half-life of 120 min, allowing for intermittent subcutaneous dosing schedules [22]. Pasireotide is the most recently derived SA and has garnered significant interest in the prevention of POPF, as it shows a broader binding affinity and a better pharmacokinetic profile than other SAs [23].

While previous trials have demonstrated the efficacy of SA prophylaxis in reducing the incidence of POPF [22–24], there has been no consensus regarding their routine prophylactic use for preventing POPF, and some studies have shown that SAs not only have no effect on the incidence of POPF [25, 26] but also incur significant additional costs [27], thus advocating against routine prophylaxis [27, 28]. Furthermore, different patient- and disease-related factors are implicated in POPF development, and many authors have proposed composite Fistula Risk Scores based on such variables [29, 30]. SA prophylaxis alone may, therefore, not be effective for reducing POPF, resulting in the need for more randomized studies to be conducted.

However, the results of numerous trials available in the literature have varied widely due to several major issues. First, many studies lack fistula risk stratification, as they predate the development of the FRS [5]. Second, there is great heterogeneity with regards to the surgeon and institutional experience, pancreatic pathologies included, kind and dosages of SA administered, type of pancreatic resection (PD versus distal pancreatectomy), reconstruction technique used, and policy concerning drain placement and removal. Third, the definition of POPF has yet to be standardized, and most previous trials predate not only the 2016 ISGPS revised POPF definition and classification [4] but also the initial ISGPF classification [3]; studies therefore have not differentiated between biochemical and clinically relevant POPF. Indeed, a recent meta-analysis by Adiamah et al. [31] of 1615 patients from 12 randomized studies including different types of SA administered concluded that the routine administration of an SA cannot be recommended.

### Table 5 Incidence of POPF

|               | No fistula | BL | Grade B | Grade C | p value |
|---------------|------------|----|---------|---------|---------|
| C group, n (%) | 57 (79.2)  | 7  | 9 (7.7) | 7 (9.7) | 1 (1.4) | 0.656   |
| Negligible, FRS = 0, n (%) | 6 (100)   | 0  | 0 (0)   | 0 (0)   |         |         |
| Low, FRS = 1–2, n (%)    | 12 (85.7) | 1  | 1 (7.1) | 1 (7.1) | 0 (0)   |         |
| Intermediate, FRS = 3–6, n (%) | 31 (75.6) | 5  | 12.2)  | 5 (12.2)| 0 (0)   |         |
| High, FRS = 7–10, n (%) | 8 (72.7) | 1  | 9 (1.1) | 1 (9.1) | 1 (9.1) |         |
| WS group, n (%)           | 56 (77.8) | 10 | 13.9)  | 6 (8.3) | 0 (0)   |         |
| Negligible, FRS = 0, n (%) | 6 (100) | 0  | 0 (0)   | 0 (0)   |         |         |
| Low, FRS = 1–2, n (%)    | 11 (78.6) | 2  | 14.3)  | 1 (7.1) | 0 (0)   |         |
| Intermediate, FRS = 3–6, n (%) | 29 (70.7) | 8  | 19.5)  | 4 (9.8) | 0 (0)   |         |
| High, FRS = 7–10, n (%) | 10 (90.9)| 0  | 0 (0)   | 1 (9.1) | 0 (0)   |         |
| Total, n (%)              | 113 (78.5)| 17 | 11.8)  | 13 (9)  | 1 (0.7) |         |

**BL** biochemical leak, **FRS** fistula risk score

### Table 6 Postoperative data

|                                 | C group | WS group | p value |
|---------------------------------|---------|----------|---------|
| Hospital stay (days), mean±SD   | 19.57 10.21 | 19.75 12.00 | 0.924   |
| Post-operative blood transfusion, n (%) | 24 (33.3) | 16 (22.2) | 0.137   |
| 30-day mortality, n (%)         | 2 (2.8) | 3 (4.2)  | 0.649   |
| Overall complications            |         |          |         |
| Cardiological, n (%)            | 5 (6.9) | 8 (11.1) | 0.383   |
| Pulmonary, n (%)                | 13 (18.1)| 10 (13.9)| 0.495   |
| Onset of diabetes, n (%)        | 9 (12.5) | 18 (25)  | 0.055   |
| Digestive bleeding, n (%)       | 2 (2.8) | 7 (9.7)  | 0.085   |
| Clavien Dindo                   |         |          | 0.936   |
| I, n (%)                        | 11 (15.3)| 12 (16.7)|         |
| II, n (%)                       | 25 (34.7)| 19 (26.4)|         |
| Illa, n (%)                     | 2 (2.8) | 2 (2.8)  |         |
| IIIb, n (%)                     | 4 (5.6) | 3 (4.2)  |         |
| IV, n (%)                       | 1 (1.4) | 2 (2.8)  |         |
| V, n (%)                        | 2 (2.8) | 3 (4.2)  |         |
| 30-day reoperation, n (%)       | 2 (2.8) | 2 (2.8)  | 1       |
following PD, as it did not improve outcomes. They included studies published after 2000 and separately analyzed studies published after 2005 to include the ISGPF definitions. However, they acknowledged a possible publication bias, as the analysis included papers by authors who did not report separately on the blinding of outcome assessors (detection bias) and claimed to include only PD studies. The studies of Sarr et al. [32], Allen et al. [33], and Katsourakis et al. [34] all included distal pancreatectomy patients.

The most recent meta-analysis by Li et al. [35] reporting on the relationship between the use of different SAs and the occurrence of POPF stands in stark contrast with the above-mentioned previous meta-analysis, concluding that SA prophylaxis significantly reduces the POPF incidence as well as overall morbidity but not mortality. However, several biases may have again affected the results of this study. First, the most recent ISGPS classification of POPF was reported in 2016 [4], and attempts at a universal definition of POPF were first performed in 2005 [3]. Therefore, each individual randomized control trial (RCT) assessed POPF using different definitions, with pre-2005 RCTs including ‘biochemical leak’ within the POPF definition, and studies from 2005 to 2016 following the first POPF classification system that, however, presents dramatic differences in comparison to the 2016 updated one. Furthermore, although the same grading system (Grades A/B/C) was used, the grades themselves were not interchangeable between the 2005 and 2016 definitions. According to the 2005 definitions [3], Grade A POPFs were called “transient fistulae”, as these POPFs require little change in management and are mostly managed by the slow removal of surgical drains. Grade B POPFs were defined as POPFs that require a change in management but, in contrast to the 2016 definitions [4], did not have a requirement of at least three weeks of prolonged drainage. Grade C POPFs, according to the 2005 definition [3], were those requiring a major change in management with aggressive intervention. The 2016 definition [4] is more specific, with Grade C POPF only applied to POPFs that lead to re-operation, single/multi-organ failure or mortality. Although the abovementioned authors tried to stratify POPFs into BL and clinically relevant POPF (define as Grade B/C POPF) based on the 2016 ISGPS definitions [4], they encountered difficulty in separating POPFs into distinct groups due to heterogeneity in the definition. Even the two most recent randomized studies available [25, 26], published after 2016, started enrolment in 2014 and used the 2005 ISGPF definitions of POPF; furthermore, both these studies were unique, as El Nakeeb et al. [26] performed pancreaticogastrostomy anastomosis, while You et al. [25] exteriorized the pancreatic stent across the pancreaticojejunoanastomosis, declining to draw definitive conclusions. Second, the FRS was proposed by Callery et al. [5] to stratify patients who might require SA prophylaxis by risk, with prophylaxis provided to those with higher scores, as also recommended by the current ISGPS position statement [15]. However, despite the fact that the FRS has been used in the past to evaluate the effectiveness of SA prophylaxis, no RCT has yet used it to stratify patients and evaluate the effectiveness of SA prophylaxis [35], especially in high-risk patients.

For these reasons, we tried to eliminate selection biases by stratifying the risk of POPF using a prospectively validated clinical risk score [5–7] involving the updated 2016 ISGPS criteria [4] for POPF definition and classification and including only patients who had undergone PD with the same pancreaticojejunoanastomotic technique (mPJ), which has been demonstrated to be a valid and safe alternative to other methods [17]. Indeed, our previous study describing this technique [17] reported a low total rate of POPF (17%), and the rate of POPF in high-risk patients according to the FRS was 18.8%, supporting the safety and efficacy of mPJ, especially for “difficult” pancreas cases with a high FRS (soft gland texture and small duct). Furthermore, when matching patients for the analysis, we also took into consideration two other patient-related risk factors for POPF: the BMI and ASA score. Several different studies have also included these intrinsic patient features in the multifactorial pathogenesis of POPF, identifying obesity as a significant predictor of POPF [36], so BMI is one of the most consistent and frequently included variables in the various risk scores proposed in the literature. Ellis et al., in a study including 15,033 PDs, confirmed a higher BMI to be a predictor of POPF both in bivariate and multivariate models [37]. Wiltberger et al. reported on the outcomes of 405 patients who underwent PD, finding that the ASA score and BMI were two independent significant predictors of postoperative major complications in their multivariate analysis [16].

The general trend has not been in favor of the routine clinical use of somatostatin or its analogues and our institutional policy of recent years was in line with this trend. However, we believe that this analysis, which aimed to overcome the previously described limitations of the available literature and provided specific information on high-risk pancreas cases, thanks to stratification, successfully added new information to a still-controversial debate. However, due to the reported considerations, this topic is far from being completely resolved.

In our series, even after adjusting for all possible confounding factors, we did not find any statistically significant difference between the two groups in terms of POPF occurrence, confirming the appropriateness of the aforementioned general trend. Furthermore, although the current position statement of the ISGPS suggests that the routine use of SAs may be relevant following pancreatoduodenectomy for high-risk patients only [15], we did not note any significant difference even when considering only the subgroups of patients at a high risk of developing POPF according to the FRS.
Thus, our experience ultimately does not support this recommendation if the aim is to prevent POPF, even in high-risk pancreata.

However, other topics of discussion have emerged from the present study. Indeed, while we found no statistically significant difference between the two groups in terms of the mortality and overall morbidity, we did note a difference in the rates of postoperative digestive bleeding, suggesting that somatostatin administration may play a role in this setting. The observed digestive bleeding rates obviously do not refer to bleeding directly related to erosive POPF but rather to minor digestive bleeding that clinically manifested as hematochezia or melena, despite the same PPI therapy being administered to all patients in both groups. Somatostatin has been proven to reduce the portal blood flow or hepatic venous pressure gradient in most experimental studies [38], so SAs are still used for the emergency treatment of bleeding oesophageal varices in cirrhotic patients. SAs are also used to treat gastrointestinal angiodysplasias, as several observational studies and meta-analyses have suggested that SAs can reduce the re-bleeding and transfusion requirements in patients with gastrointestinal angiodysplasias bleeding refractory to or inaccessible by endoscopic therapies [39]. Furthermore, multiple studies have correlated SAs with a reduction in the pancreatic perfusion and gastroduodenal mucosal blood flow [40–43], and this reduction seems to selectively affect the splanchic circulation without altering the systemic circulation [42]. McMillan et al. [44], in a retrospective study including a risk-adjusted analysis of 1018 patients who had undergone PD, reported that SA administration not only did not lead to any clinical benefit but was associated with an increased rate of POPF, especially in high-risk patients. The authors explained that these results suggested that the change in pancreatic and gastroduodenal perfusion caused by SA resulted in a reduced anastomotic perfusion, thereby promoting ischemia and congestion at the site of the pancreatic anastomosis, limiting or impairing the wound healing, and consequently increasing the risk of POPF. In contrast, we found no notably high rate of POPF in the C group, so we suspect that the regionalized ischemia induced by somatostatin was the reason for the lower rate of postoperative digestive bleeding in the C group, despite no observable effect on POPF development. Even if our results concerning this point are not statistically significant and the digestive bleeding observed was not clinically relevant, further studies should investigate the possible role of somatostatin in patients at a high risk of bleeding rather than in those with a high FRS.

The other interesting result that emerged from this study was the rate of the onset of diabetes, which was higher in the WS group to a nearly significant degree. The involvement of hyperglucagonemia, which is suspected to be even more important than insulin deficiency in the pathogenesis of diabetes [45], might explain this result. Indeed, patients with diabetes are characterized by not only a compromised insulin secretion and action but also paradoxically elevated plasma concentrations of glucagon that fail to decline appropriately or even increase in response to an oral glucose tolerance test (OGTT) [46]. Thus, somatostatin may represent an attractive approach for treating post-pancreatectomy diabetes by reducing glucagon secretion and improving glucose tolerance. Previous reports have shown that both the fasting and postprandial blood glucose levels during OGTT decreased after the administration of somatostatin in patients who had undergone total pancreatectomy [45, 47, 48], suggesting an extrapancreatic origin of postprandial hyperglucagonemia. Indeed, the discovery of extrapancreatic glucagon secretion and the postprandial hyperglucagonemia observed in totally pancreatectomized patients has changed the concept of glucagon to a pancreas-specific hormone and thus proposed the theory of postprandial hyperglucagonemia as a gut-dependent phenomenon [46]. Glucagon is a product of the preproglucagon gene (GCG), which is expressed by both pancreatic α-cells and specific enteroendocrine cells (L cells) of the intestinal mucosa and neurons within the nucleus of the solitary tract. It is, therefore, possible that the proglucagon-containing enteroendocrine L cells may be the origin of the extrapancreatic glucagon secretion. In this regard, the results of the study by Lund et al. [46] raise the interesting possibility of an increased recruitment of GCG-expressing cells in pancreatectomized patients as a response to the removal of the pancreatic α-cells. These considerations are not totally applicable to our study, as our cohort did not undergo total pancreatectomy. Unfortunately, there are no data available at present concerning PD, so further studies will be needed to better understand the possible role of somatostatin in preventing the onset of postoperative diabetes in this setting.

A final aspect to consider concerns the different SAs available and tested in addition to somatostatin, such as octreotide, vapreotide, and pasireotide. These SAs have varying pharmacokinetic and pharmacodynamic profiles. In the present study, we only considered patients treated with somatostatin, as it historically represents the most commonly used SA at our institution as well as the most economically viable one. Both of the most recent meta-analyses mentioned above [31, 35] are limited by their consideration of all SAs indifferently, and thus far, there have been no randomized trials comparing two or more different analogues. Every SA has always been studied individually, with different and controversial results. Pasireotide seems to be the most promising of the currently available SAs, as Allen et al. found in their 2014 study, the only randomized double-blinded trial available in the literature [33]. Those authors found prophylactic pasireotide to be effective for reducing POPF. However,
subsequent studies have not unanimously confirmed these encouraging results, so further studies are required.

In conclusion, despite the limitations of this study, mainly due to its retrospective nature and relatively small sample size, we used a rigorous case-match methodology stratifying patient according to the main risk factors: FRS, ASA score, and BMI. In addition, the surgical approach to pancreatic reconstruction was standardized [17], and POPF was strictly defined and classified using the new ISGPS grading [4] to reduce bias. The results of the present study confirm no benefit associated with the routine administration of somatostatin after PD to prevent POPF, not even in high-risk patients, and not even in terms of the overall postoperative morbidity and mortality. However, although not statistically significant, improved outcomes in terms of postoperative digestive bleeding and diabetes onset were observed in patients treated with somatostatin, suggesting once again that the debate on the use of SAs following PD is far from over. Further studies are necessary to validate these results and draw definitive conclusions.

Acknowledgements The authors thank the Tizzi Foundation, Rotary Foundation, Arpa Foundation and Orvietani’s Family for their support. The authors also thank Sharon Bernadette King for the language editing.

Funding Open access funding provided by Università di Pisa within the CRUI-CARE Agreement. This research did not receive any specific grant from funding agencies in the public, commercial, or non-profit sectors.

Compliance with ethical standards Conflict of interest The authors declare that they have no conflict of interest.

Ethical standards All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Yoshioka R, Yasunaga H, Hasegawa K, Horiguchi H, Fushimi K, Aoki T, et al. Impact of hospital volume on hospital mortality, length of stay and total costs after pancreaticoduodenectomy. Br J Surg. 2014;101(5):523–9.
2. Pedrazzoli S. Pancreato-duodenectomy (PD) and postoperative pancreatic fistula (POPF). Med (United States). 2017. https://doi.org/10.1097/M.D.0000000000006858.
3. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPS) definition. Surgery. 2005;138:8–13.
4. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:384–91.
5. Callery MP, Pratt WB, Kent TS, Chai kof EL, Vollmer CMA Jr. prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreato-duodenectomy. J Am Coll Surg. 2013;216(1):1–14.
6. Miller BC, Christein JD, Behrman SW, Dreb lin JA, Pratt WB, Callery MP, et al. A multi-institutional external validation of the Fistula Risk Score for pancreaticoduodenectomy. J Gastrointest Surg. 2014;18(1):172–9 (discussion 179–80).
7. Shubert CR, Wagle AE, Farnell MB, Nagorney DM, Que FG, Lombardo KMR, et al. Clinical risk score to predict pancreatic fistula after pancreato duodenectomy: independent external validation for open and laparoscopic approaches. J Am Coll Surg. 2015;221(3):689–98.
8. ASA House of Delegates/Executive Committee. Schaumburg (IL): American Society of Anesthesiologists; 2014. ASA physical status classification system [Internet]. Oct 15 [accessed 11 April 2020]. Available from https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system.
9. Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL, Fisher ES. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery. 1999;125:250–6.
10. Gouma DJ, van Geenen RC, van Gulik TM, Thomas M, de Haan RJ, de Wit LT, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg. 2000;232:786–95.
11. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10–5.
12. Butturini G, Daskalaki D, Molinari E, Scopelliti F, Casarotto A, Bassi C. Pancreatic fistula: definition and current problems. J Hepatobiliary Pancreat Surg. 2008;15:247–51.
13. Poon RT, Lo SH, Fong D, Fan ST, Wong J. Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am J Surg. 2002;183:42–52.
14. Klem pa I, Schwedes U, Usadel KH. Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin. Chirurg. 1979;50:427–31.
15. Shrikhande SV, Sivasanker M, Vollmer CM, Friess H, Besselin MG, Fingerhut A, et al. Pancreatic anastomosis after pancreaticoduodenectomy: a position statement by the international study group of pancreatic surgery (ISGPS). Surgery. 2017;161:1221–34.
16. Wilber ger G, Muhl B, Benzing C, Atanasov G, Hau HM, Horn M, et al. Preoperative risk stratification for major complications following pancreaticoduodenectomy. Int J Surg. 2016;31:33–9. https://doi.org/10.1016/j.ijsu.2016.04.034.
17. Morelli L, Di Franco G, Guadagni S, Palmeri M, Furbetta N, Gianardi D, et al. Technical details and results of a modified endo-side technique of pancreatojejunostomy: a personal series of 100 patients. J Gastrointest Surg. 2017. https://doi.org/10.1007/s11605-017-3587-7.
18. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.

19. Wang SE, Chen SC, Shyr BU, Shyr YM. Comparison of Modified Blumgart pancreaticojejunostomy and pancreaticogastrostomy after pancreaticoduodenectomy. HPB (Oxford). 2016;18(3):229–35.

20. Kleebeys A, Albertsmeyer M, Obeidat F, Seeliger H, Jauch K-W, Brunns CJ. The challenge of pancreatic anastomosis. Langenbeck’s Arch Surg. 2008;393(4):459–71.

21. Grobmyer SR, Kooby D, Blumgart LH, Hochwald SN. Novel pancreaticojejunostomy with a low rate of anastomotic failure related complications. J Am Coll Surg. 2010;210(1):54–9.

22. Berberat PO, Friess H, Uhl W, Buchler MW. The role of octreotide in the prevention of complications following pancreatic resection. Digestion. 1999;60(Suppl 2):15–22.

23. Ma LW, Dominguez-Rosado I, Gennarelli RL, Bach PB, Gonen M, D’Angelica MI, et al. The cost of postoperative pancreatic fistula versus the cost of postoperative: results from a prospective randomized trial. Ann Surg. 2017;265(1):11–6.

24. Kurumboor P, Palaniswami KN, Pramil K, George D, Ponnambahayil S, Varma D, et al. Octreotide does not prevent pancreatic fistula following pancreaticoduodenectomy in patients with soft pancreas and non-dilated duct: a prospective randomized controlled trial. J Gastrointest Surg. 2015;19(1):2038–44.

25. You DD, Paik KY, Park YJ, Yoo YK. Randomized controlled study of the effect of octreotide on pancreatic exocrine secretion and pancreatic fistula after pancreaticoduodenectomy. Asian J Surg. 2019;42(2):548–63.

26. El Nakeeb A, ElGawalby A, Ali MA, Shehta A, Hamed H, El Refa El, et al. Efficacy of octreotide in the prevention of complications after pancreaticoduodenectomy in patients with soft pancreas and non-dilated pancreatic duct: a prospective randomized trial. Hepatobiliary Pancreat Dis Int. 2018;17(1):59–63.

27. Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg. 2000;232(3):419–29.

28. Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997;226(5):632–41.

29. Mungroop TH, van Rijssen LB, van Klaveren D, Smits SJ, van Woerden V, Linnemann RJ, et al. Alternative Fistula Risk Score for pancreaticoduodenectomy (a-FRS): design and international external validation. Ann Surg. 2019;269(5):937–43.

30. Shamali A, Shelat V, Jaber B, Wardak A, Ahmed M, Fontana M, et al. Impact of obesity on short and long term results following a pancreatic-duodenectomy. Int J Surg. 2017;42:191–6.

31. Adimah A, Arif Z, Berti F, Singh S, Laskar N, Gomez D. The use of prophylactic somatostatin therapy following pancreaticoduodenectomy: a meta-analysis of randomised controlled trials. World J Surg. 2019;43(7):1788–801.

32. Sarr MG. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreaticectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg. 2003;196(4):556–64.

33. Allen PJ, Gonen M, Brennan MF, Bucknor AA, Robinson LM, Pappas MM, et al. Pasireotide for postoperative pancreatic fistula. N Engl J Med. 2014;370(21):2014–22.

34. Katsourakis A, Oikonomou L, Chatzitheoklitos E, Nousios G, Pitiakoudis M, Polychronidis A, et al. The role of somatostatin in 67 consecutive pancreaticectomies: a randomized clinical trial. Clin Exp Gastroenterol. 2010;3:179–83.

35. Li T, D’Cruz RT, Lim SY, Shelat VG. Somatostatin analogues and the risk of post-operative pancreatic fistulas after pancreatic resection—a systematic review and meta-analysis. Pancreatology. 2020. https://doi.org/10.1016/j.pan.2019.12.015.

36. Sandini M, Malleo G, Gianotti L. Scores for prediction of Fistula after pancreaticoduodenectomy: a systematic review. Dig Surg. 2016;33:392–400. https://doi.org/10.1159/000445068.

37. Ellis RJ, Brock Hewitt D, Liu JB, Cohen NE, Merkow RP, Bentrem DJ, et al. Preoperative risk evaluation for pancreatic fistula after pancreaticoduodenectomy. J Surg Oncol. 2019;119:1128–34. https://doi.org/10.1002/jso.25464.

38. Gutzsche PC, Hróbjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev. 2008;3:CD000193. https://doi.org/10.1002/14651858.CD000193.pub3.

39. Benamouzig R, Benallaoua M, Saurin J-C, Boubaya L, Cellier C, Laugier R, et al. Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodyplasias: results of the ANGIOPAS multicenter phase II non-comparative prospective double-blinded randomized study. Ther Adv Gastroenterol. 2018;11:1–13. https://doi.org/10.1177/1756283X18756260.

40. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35(Suppl 1):S1–4.

41. Samnegard H, Tyden G, Thulin L, Friman L, Uden R. Effect of somatostatin on regional splanchic blood flows in man. Angiographic studies. Acta Chir Scand Suppl. 1980:500:71–3.

42. Bosch J, Kравetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology. 1981;80:518–25.

43. Villanueva C, Ortiz J, Minana J, Soriano G, Sabat M, Boadas J, et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology. 2001;121:110–7.

44. Mc Millan MT, Christein JD, Mallard DP, Drew KA, J, et al. Prophylactic octreotide for pancreaticoduodenectomy: more harm than good? HPB. 2014;16:954–62.

45. Rivelle JP, Boudou P, Blondeau B, Gautier JF. Glucagon—secretion inhibition using somatostatin: an old hormone for the treatment of diabetes-associated pancreaticectomies. Diabetes Metab. 2017;43:269–71.

46. Lund A, Baggar JI, Wewer Albrechtsen NJ, Christensen M, Grønhold M. The challenge of pancreatic anastomosis. Langenbeck’s Arch Chir. 2016;18(3):229–35.

47. Bringer J, Mirouze J, Marchal G, et al. Glucagon immunoreactivity and anti-diabetic action of somatostatin in the totally duodenopancreatectomized and gastrectomized human. Diabetes. 1981;30:851–6.

48. Okuma H, Bouchi R, Masuda S, Takeuchi T, Murakami M, Minami I, et al. Suppression of extrapancreatic glucagon by octreotide versus the cost of pasireotide: results from a prospective randomized clinical trial. Adv Gastroenterol. 2018;11:1–13. https://doi.org/10.1177/1756283X18756260.

49. Sugden K, Dyer P, Coster DJ, Jeffs RG. Suppression of extrapancreatic glucagon by octreotide: a randomized controlled trial. Clin Exp Gastroenterol. 2010;3:179–83.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.